8,9-Dehydroestrone

8,9-Dehydroestrone
Clinical data
Other names	Δ8-Estrone; Estra-1,3,5(10),8-tetraen-3-ol-17-one
Routes of; administration	By mouth
Drug class	Estrogen
Identifiers
	IUPAC name (13S,14S)-3-Hydroxy-13-methyl-7,11,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-one;
CAS Number	474-87-3;
PubChem CID	6451472;
ChemSpider	4953937;
UNII	7C1N8RKG9F;
CompTox Dashboard (EPA)	DTXSID40197125 ;
Chemical and physical data
Formula	C18H20O2
Molar mass	268.350 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CCC3=C([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O;
	InChI InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,16,19H,2,4,6-9H2,1H3/t16-,18-/m0/s1; Key:OUGSRCWSHMWPQE-WMZOPIPTSA-N;

8,9-Dehydroestrone, or Δ⁸-estrone, also known as estra-1,3,5(10),8-tetraen-3-ol-17-one, is a naturally occurring estrogen found in horses which is closely related to equilin, equilenin, and estrone, and, as the 3-sulfate ester sodium salt, is a minor constituent (3.5%) of conjugated estrogens (Premarin).[1][2][3][4] It produces 8,9-dehydro-17β-estradiol as an important active metabolite, analogously to conversion of estrone or estrone sulfate into estradiol.[2][4][5][3] The compound was first described in 1997.[6][3] In addition to 8,9-dehydroestrone and 8,9-dehydro-17β-estradiol, 8,9-dehydro-17α-estradiol is likely also to be present in conjugated estrogens, but has not been identified at this time.[2]

Composition of conjugated estrogens and properties of constituents
Compound	Synonym	Proportion (%)	Relative potency in the vagina (%)	Relative potency in the uterus (%)	RBA for ERα (%)	RBA for ERβ (%)	ERα / ERβ RBA ratio
Conjugated estrogens	–	100	38	100	–	–	–
Estrone	–	49.1–61.5	30	32	26	52	0.50
Equilin	Δ⁷-Estrone	22.4–30.5	42	80	13	49	0.26
17α-Dihydroequilin	Δ⁷-17α-Estradiol	13.5–19.5	0.06	2.6	41	32	1.30
17α-Estradiol	–	2.5–9.5	0.11	3.5	19	42	0.45
Δ⁸-Estrone	–	3.5–3.9	?	?	19	32	0.60
Equilenin	Δ^6,8-Estrone	2.2–2.8	1.3	11.4	15	20–29	0.50–0.75
17β-Dihydroequilin	Δ⁷-17β-Estradiol	0.5–4.0	83	200	113	108	1.05
17α-Dihydroequilenin	Δ^6,8-17α-Estradiol	1.2–1.6	0.018	1.3	20	49	0.40
17β-Estradiol	–	0.56–0.9	100	?	100	100	1.00
17β-Dihydroequilenin	Δ^6,8-17β-Estradiol	0.5–0.7	0.21	9.4	68	90	0.75
Δ⁸-17β-Estradiol	–	Small amounts	?	?	68	72	0.94
Notes: All listed compounds are present in conjugated estrogen products specifically in the form of the sodium salts of the sulfate esters (i.e., as sodium estrone sulfate, sodium equilin sulfate, etc.). Sources: See template.

References

Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–. ISBN 978-1-4511-4847-3.
Bhavnani BR (January 1998). "Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism". Proc. Soc. Exp. Biol. Med. 217 (1): 6–16. doi:10.3181/00379727-217-44199. PMID 9421201.
Bhavnani BR, Cecutti A, Gerulath A (October 1998). "Pharmacokinetics and pharmacodynamics of a novel estrogen delta8-estrone in postmenopausal women and men". J. Steroid Biochem. Mol. Biol. 67 (2): 119–31. doi:10.1016/s0960-0760(98)00082-x. PMID 9877212.
Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A (June 1999). "Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women". J. Clin. Endocrinol. Metab. 84 (6): 2020–7. doi:10.1210/jcem.84.6.5800. PMID 10372704.
Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
Bhavnani B. R., Cecutti A. and Dey M. S., Effects in postmenopausal women of delta-8-estrone sulfate: A novel estrogen component of Premarin. Journal Society Gynecologic Investigation 4 (1 (Suppl.)) (1997) 392.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[FritzSperoff2012-1] Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–. ISBN 978-1-4511-4847-3.

[pmid9421201-2] Bhavnani BR (January 1998). "Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism". Proc. Soc. Exp. Biol. Med. 217 (1): 6–16. doi:10.3181/00379727-217-44199. PMID 9421201.

[pmid9877212-3] Bhavnani BR, Cecutti A, Gerulath A (October 1998). "Pharmacokinetics and pharmacodynamics of a novel estrogen delta8-estrone in postmenopausal women and men". J. Steroid Biochem. Mol. Biol. 67 (2): 119–31. doi:10.1016/s0960-0760(98)00082-x. PMID 9877212.

[pmid10372704-4] Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A (June 1999). "Estrogen activity and novel tissue selectivity of delta8,9-dehydroestrone sulfate in postmenopausal women". J. Clin. Endocrinol. Metab. 84 (6): 2020–7. doi:10.1210/jcem.84.6.5800. PMID 10372704.

[pmid16112947-5] Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.

[BhavnaniCecutti1997-6] Bhavnani B. R., Cecutti A. and Dey M. S., Effects in postmenopausal women of delta-8-estrone sulfate: A novel estrogen component of Premarin. Journal Society Gynecologic Investigation 4 (1 (Suppl.)) (1997) 392.

8,9-Dehydroestrone

See also

References